| CBOE |
Report |
Adjusted diluted EPS |
BEAT |
pred ~$3.58 vs. cons $3.46 |
MEDIUM |
| CBOE |
Report |
Net revenue |
BEAT |
pred ~$737M vs. cons $714M |
MEDIUM |
| CBOE |
Report |
Total options RPC |
IN-LINE |
pred ~$0.319 vs. cons $0.317 |
MEDIUM |
| CBOE |
Guide |
Organic total net-revenue growth |
UNCHANGED |
guide ~14% midpoint (low-double-digit to mid-teens) vs. cons 14% (FY2026) |
MEDIUM |
| CBOE |
Guide |
Adjusted operating expense |
UNCHANGED |
guide ~$846M midpoint ($838M-$853M) vs. cons $846M (FY2026) |
HIGH |
| CBOE |
Guide |
Data Vantage organic net-revenue growth |
UNCHANGED |
guide ~10% (low-double-digit) vs. cons 10% (FY2026) |
MEDIUM |
| CBOE |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.8% |
— |
MEDIUM |
| CBOE |
Return |
5-day cumulative residual |
+0.8% (STABILIZE) |
A ~$3.58 EPS versus $3.46 consensus beat and ~$737M revenue versus $714M should support an initially positive response, but a ~$0.319 options RPC versus $0.317 and unchanged FY2026 organic-growth and opex guide leave limited out-period estimate upside. The initial gain should stabilize rather than extend materially as revisions remain modest. |
MEDIUM |